In the News
PPD adds biologics testing to GMP lineup in Ireland
The company’s goal is to offer the same extensive biologic, gene and cell therapy portfolio to clients in both Europe and North America.
Osteoporosis: Addressing the unmet need
Rose Blackburne and Davide Garrisi provide an overview of the osteoporosis landscape and the associated regulatory environment.
Planning and execution
In this article from PPD and PPD-SNBL, the authors discuss key factors to consider when developing a pharmacovigilance presence in Japan.
Trend: R&D modeling and simulation
Evidera’s Anuraag Kansal discusses the impact computer simulation has on the understanding of and hypotheses around a clinical trial.
PPD discusses lab trends at AAPS 2018
Heather Myler of PPD® Laboratories offers her thoughts on labs trends.
PPD unveils new additions in a number of therapeutic areas
PPD strengthens drug development expertise with new therapeutic professionals.
The impact of vortexing on the particle-size distribution of pharmaceuticals
Greg Maj, Jeff Driscoll, Eric Olson and Jonathon Salsbury report on a study that compares the applied shear to sample suspensions of ibuprofen to observe the effects of applied shear on the particle size distribution.
Ensuring Employees’ Well-Being In The Eye Of A Storm
Ron Garrow discusses how in the wake of Hurricane Florence that our employees’ well-being comes first.
An analytical approach to biosimilar drug development
Patricia Hurley, Edward Tabler and Duu-Gong Wu talk about the impact that analytical testing on biosimilars has on their pathway to regulatory approval.
